Eribulin Mesylate 0.44 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 0.44 mg/mL

Reference Brands: HALAVEN (USA/EU)

Category: Oncology Cancer Care

Eribulin mesylate is a microtubule dynamics inhibitor derived from the marine sponge Halichondria okadai. It is used for the treatment of patients with metastatic breast cancer and unresectable or metastatic liposarcoma who have received prior chemotherapy. The drug works by inhibiting microtubule growth, leading to cancer cell cycle arrest and apoptosis. Halaven is administered intravenously under medical supervision and is recognized for extending survival in patients with advanced cancer.

Product Description:

Eribulin is a simplified synthetic version of halichondrin B, a molecule found in a marine sponge and far too complex and scarce to harvest. It binds the growing ends of microtubules and blocks their extension without affecting shortening, which is a different action from the taxanes and the vinca alkaloids and explains why it retains activity in tumours that have already failed both. It also appears to remodel tumour vasculature and reverse the epithelial-mesenchymal transition.

It is used for metastatic breast cancer after at least two prior chemotherapy regimens for advanced disease, and for unresectable or metastatic liposarcoma after an anthracycline. Its distinction is that it demonstrated an overall survival gain, not merely delayed progression, in heavily pretreated breast cancer. Neutropenia is the dose-limiting toxicity. Peripheral neuropathy is cumulative and may persist; fatigue, alopecia and nausea are common. It is given as a short intravenous injection, which suits day-unit throughput.

Sourcing notes. Originator product; patent expiry has begun in some territories and generic entry is emerging, but the synthesis is unusually long and few manufacturers have attempted it, so multi-source supply remains thin. Ready-to-use solution, no reconstitution. Cytotoxic handling.